P-941 Phase II study of gefitinib (IRESSA) administered as first linetreatment in patients with non-resectable, pneumonic-type adenocarcinoma (P-ADC)

Authors :: Sylvie Friard
P. Debove
D. Morot-Sibilot
J-C. Soria
Pierre-Jean Souquet
A. Vergnenegre
Maurice Pérol
B. Milleron
E. Quoix
Jacques Cadranel
Source :: Lung Cancer. 49:S367
Publication Year :: 2005
Publisher :: Elsevier BV, 2005.

Subjects :: Pulmonary and Respiratory Medicine
Oncology
Cancer Research
medicine.medical_specialty
business.industry
Phases of clinical research
medicine.disease
Gefitinib
Internal medicine
medicine
Adenocarcinoma
In patient
business
medicine.drug

Full Text Access

Tools